Novel medical therapies for pulmonary arterial hypertension

Clinics in Chest Medicine

Volumn 34, Issue 4, 2013, Pages 867-880

  O'Connell, Caroline ^a   O'Callaghan, Dermot S ^a   Humbert, Marc ^b,c,d  

^a MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^b Paris South University   (France)

^c BICÊTRE HOSPITAL   (France)

^d Universite Paris Sud   (France)

Author keywords

Endothelial progenitor cells; Endothelin receptor antagonists; Guanylate cyclase stimulators; Prostacyclin receptor agonists; Rho kinase inhibitors; Tyrosine kinase inhibitors

Indexed keywords

ATORVASTATIN; BERAPROST; BISOPROLOL; BOSENTAN; CARDICOR; DASATINIB; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; FLUOXETINE; IMATINIB; MACITENTAN; NILOTINIB; NITRIC OXIDE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTACYCLIN; PROSTANOID; RIOCIGUAT; SELEXIPAG; SENATEK; SEROTONIN; SILDENAFIL; SIMVASTATIN; SORAFENIB; TADALAFIL; TERGURIDE; TEZOSENTAN; TREPROSTINIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VARDENAFIL; VASOACTIVE INTESTINAL POLYPEPTIDE; WARFARIN;

ADVERSE OUTCOME; ALOPECIA; ANEMIA; CARDIOTOXICITY; CATHETER INFECTION; CATHETER THROMBOSIS; CHRONIC MYELOID LEUKEMIA; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; CONTINUOUS INFUSION; DIARRHEA; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; ENDOTHELIAL PROGENITOR CELL; FACE EDEMA; GASTROINTESTINAL DISEASE; HAND FOOT SYNDROME; HEADACHE; HUMAN; HYPERPROLACTINEMIA; HYPOKALEMIA; LOW DRUG DOSE; LUNG FIBROSIS; MYELOID LEUKEMIA; NAUSEA; NONHUMAN; OUTCOME ASSESSMENT; PERIORBITAL EDEMA; PERIPHERAL EDEMA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RASH; REVIEW; UNSPECIFIED SIDE EFFECT; VOMITING;

ENDOTHELIAL PROGENITOR CELLS; ENDOTHELIN RECEPTOR ANTAGONISTS; GUANYLATE CYCLASE STIMULATORS; PROSTACYCLIN RECEPTOR AGONISTS; RHO-KINASE INHIBITORS; TYROSINE KINASE INHIBITORS;

GUANYLATE CYCLASE; HUMANS; HYPERTENSION, PULMONARY; PYRAZOLES; PYRIMIDINES; RECEPTORS, ENDOTHELIN; RECEPTORS, EPOPROSTENOL; SULFONAMIDES;

EID: 84888186611     PISSN: 02725231     EISSN: 15578216     Source Type: Journal    
DOI: 10.1016/j.ccm.2013.08.002     Document Type: Review

References (113)

1. O'Callaghan D., Savale L., Montani D., et al. Treatment of pulmonary arterial hypertension with targeted therapies. Nat Rev Cardiol 2011, 8:526-538.
2. Humbert M., Sitbon O., Chaouat A., et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010, 122(2):156-163.
3. D'Alonzo G., Barst R., Ayres S., et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991, 115(5):343-349.
4. Giaid A., Yanagisawa M., Langleben D., et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. NEngl J Med 1993, 328(24):1732-1739.
5. Humbert M., Segal E., Kiely D., et al. Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J 2007, 30(2):338-344.
6. O'Connell C., O'Callaghan D., Gaine S. New drugs for pulmonary hypertension. Eur Respir Monogr 2012, 57(19):233-246.
7. Raghu G., Million-Rousseau R., Morganti A., et al. Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial. Eur Respir J 2013, [Epub ahead of print]. 10.1183/09031936.00104612.
8. Iglarz M., Binkert C., Morrison K., et al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. JPharmacol Exp Ther 2008, 327(3):736-745.
9. Kummer O., Haschke M., Hammann F., et al. Comparison of the dissolution and pharmacokinetic profiles of two galenical formulations of the endothelin receptor antagonist macitentan. Eur J Pharm Sci 2009, 38(4):384-388.
10. Sidharta P., van Giersbergen P., Halabi A., et al. Macitentan: entry-into-humans study with a new endothelin receptor antagonist. Eur J Clin Pharmacol 2011, 67(10):977-984.
11. Raja S. Macitentan, a tissue-targeting endothelin receptor antagonist for the potential oral treatment of pulmonary arterial hypertension and idiopathic pulmonary fibrosis. Curr Opin Investig Drugs 2010, 11(9):1066-1073.
12. Pulido T., Adzerikho I., Channick R., et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013, 369(9):809-818.
13. Christman B., McPherson C., Newman J., et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. NEngl J Med 1992, 327(2):70-75.
14. Barst R., Rubin L., McGoon M., et al. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994, 121(6):409-415.
15. US NIH ClinicalTrials.gov. Study of a new thermo stable formulation of epoprostenol sodium to treatpulmonary arterial hypertension (PAH). Available at: Last updated October 18, 2012. Last Accessed September 29, 2013. http://www.clinicaltrials.gov/ct2/show/NCT01462565?term=veletri%26rank=12011.
16. Sitbon O., Delcroix M., Bergot E., et al. EPITOME-2, An open-label study evaluating a new formulation of epoprostenol sodium in pulmonary arterial hypertension patients switched from Flolan. Am J Resp Crit Care Med 2012, 10.1164/ajrccm-conference.2012.185.1_MeetingAbstracts.A2500.
17. Farber H., Miller D., Meltzer L., et al. Treatment of patients with pulmonary arterial hypertension at the time of death or deterioration to functional classIV: Insights from the REVEAL registry. J Heart Lung Transplant 2013, pii: S1053-2498(13)01392-2. [Epub ahead of print].
18. Tapson V., Torres F., Kermeen F., et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Chest 2012, 142(6):1383-1390.
19. US NIH ClinicalTrials.gov. A 16-week, international, multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of oral UT-15C sustained release tablets in subjects with pulmonary arterial hypertension (FREEDOM-C2). Available at: Last updated December 7, 2012. Last Accessed September 29, 2013. http://www.clinicaltrials.gov/ct2/show/NCT00887978?term=FREEDOM-C2%26rank=12011.
20. United Therapeutics. UT-15C treprostinil diethanolamine sustained release tablets (oral treprostinil). Available at: Last Accessed September 29, 2013. http://www.unither.com/oral-treprostinil-for-pah.
21. US NIH ClinicalTrials.gov. FREEDOM - M: oral treprostinil as monotherapy for the treatment of pulmonary arterial hypertension (PAH). Available at:. Last updated February 12, 2013. Last Accessed September 29, 2013. http://www.clinicaltrials.gov/ct2/show/NCT00325403?term=FREEDOM-M%26rank=12012.
22. US NIH ClinicalTrials.gov. Trial of the early combination of oral treprostinil with a PDE-5 inhibitor or ERA in subjects with pulmonary arterial hypertension (FREEDOM-Ev) [Internet]. Available at: Last updated September 20, 2013. Last Accessed September 29, 2013. http://www.clinicaltrials.gov/ct2/show/NCT01560624?term=FREEDOM-Ev%26;rank=1.
23. Barst R., McGoon M., McLaughlin V., et al. Beraprost therapy for pulmonary arterial hypertension. JAm Coll Cardiol 2003, 41(12):2119-2125.
24. US NIH Clinicaltrials.gov. A multinational, multicenter study to assess the efficacy and safety of BPS-314d-MR in subjects with pulmonary arterial hypertension currently receiving treatment with anendothelin receptor antagonist and or a phosphodiesterase-5 inhibitor. Available at: Last updated September 26, 2013. Last Accessed September 29, 2013. http://clinicaltrialsfeeds.org/clinical-trials/show/NCT01458236.
25. Voswinckel R., Reichenberger F., Gall H., et al. Metered dose inhaler delivery of treprostinil for the treatment of pulmonary hypertension. Pulm Pharmacol Ther 2009, 22(1):50-56.
26. Gomberg-Maitland M., Olschewski H. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J 2008, 31(4):891-901.
27. Kuwano K., Hashino A., Asaki T., et al. 2-[4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]-N-(methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug. JPharmacol Exp Ther 2007, 322(3):1181-1188.
28. Simonneau G., Torbicki A., Hoeper M., et al. Selexipag, an oral, selective IP receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J 2012, 40(4):874-880.
29. McLaughlin V. Looking to the future: a new decade of pulmonary arterial hypertension therapy. Eur Respir Rev 2011, 20(122):262-269.
30. US NIH ClinicalTrials.gov. ACT-293987 in pulmonary arterial hypertension. Available at: Last updated September 3, 2013. Last Accessed September 29, 2013. http://www.clinicaltrials.gov/ct2/show/NCT01106014?term=GRIPHON%26rank=1.
31. Archer S., Michelakis E. Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension. NEngl J Med 2009, 361(19):1864-1871.
32. Ivy D., Parker D., Doran A., et al. Acute hemodynamic effects and home therapy using a novel pulsed nasal nitric oxide delivery system in children and young adults with pulmonary hypertension. Am J Cardiol 2003, 92(7):886-890.
33. Channick R., Newhart J., Johnson F., et al. Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension: an ambulatory delivery system and initial clinical tests. Chest 1996, 109(6):1545-1549.
34. Galie N., Ghofrani H., Torbicki A., et al. Sildenafil citrate therapy for pulmonary arterial hypertension. NEngl J Med 2005, 353(20):2148-2157.
35. Galie N., Brundage B., Ghofrani H., et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009, 119(22):2894-2903.
36. Corbin J., Beasley A., Blount M., et al. Vardenafil: structural basis for higher potency over sildenafil in inhibiting cGMP-specific phosphodiesterase-5 (PDE5). Neurochem Int 2004, 45(6):859-863.
37. Jing Z., Jiang X., Wu B., et al. Vardenafil treatment for patients with pulmonary arterial hypertension: a multicentre, open-label study. Heart 2009, 95(18):1531-1536.
38. Jing Z., Yu Z., Shen J., et al. Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study. Am J Respir Crit Care Med 2011, 183(12):1723-1729.
39. Evgenov O., Pacher P., Schmidt P., et al. NO-independentstimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 2006, 5(9):755-768.
40. Grimminger F., Weimann G., Frey R., et al. First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur Respir J 2009, 33(4):785-792.
41. Lang M., Kojonazarov B., Tian X., et al. The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats. PLoS One 2012, 7(8):e43433.
42. Ghofrani H., Hoeper M., Halank M., et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. Eur Respir J 2010, 36(4):792-799.
43. Rubin L., Galie N., Grimminger F., et al. Riociguat for the treatment of pulmonary arterial hypertension (PAH): a phase III long-term extension study (PATENT-2). Am J Respir Crit Care Med 2013, Available at:. http://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2013.187.1_MeetingAbstracts.A3531.
44. Ghofrani H., Galie N., Grimminger F., et al. Riociguat for the treatment of pulmonary arterial hypertension. NEngl J Med 2013, 369:330-340.
45. Ghofrani H., D'Armini A., Grimminger F., et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. NEngl J Med 2013, 369:319-329.
46. Ghofrani H., Osterloh I., Grimminger F. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov 2006, 5(8):689-702.
47. US NIH ClinicalTrials.gov. Evaluation of the pharmacodynamic effect of the combination of sildenafil and riociguat on blood pressure and other safety parameters (PATENT PLUS). Available at: Last updated May 21, 2013. Last Accessed September 29, 2013. http://clinicaltrials.gov/ct2/show/NCT01179334.
48. de Man F., Handoko M., van Ballegoij J., et al. Bisoprolol delays progression towards right heart failure in experimental pulmonary hypertension. Circ Heart Fail 2012, 5(1):97-105.
49. So P., Davies R., Chandy G., et al. Usefulness of beta-blocker therapy and outcomes in patients with pulmonary arterial hypertension. Am J Cardiol 2012, 109(10):1504-1509.
50. Perros F., Montani D., Dorfmuller P., et al. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2008, 178(1):81-88.
51. Schermuly R., Dony E., Ghofrani H., et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. JClin Invest 2005, 115(10):2811-2821.
52. Ghofrani H., Morrell N., Hoeper M., et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med 2010, 182(9):1171-1177.
53. Hoeper M., Barst R., Bourge R., et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation 2013, 127(10):1128-1138.
54. Fernández A., Sanguino A., Peng Z., et al. An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic. JClin Invest 2007, 117(12):4044-4054.
55. Kim T., le Coutre P., Schwarz M., et al. Clinical cardiac safety profile of nilotinib. Haematologica 2012, 97(6):883-889.
56. US NIH ClinicalTrials.gov. Efficacy, safety, tolerability and pharmacokinetics (PK) of nilotinib (AMN107) in pulmonary arterial hypertension. Available at: Last updated March 25, 2013. Last Accessed September 29, 2013. http://clinicaltrials.gov/ct2/show/NCT01179737?term=Nilotinib+pulmonary%26rank=12010.
57. Moreno-Vinasco L., Gomberg-Maitland M., Maitland M., et al. Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension. Physiol Genomics 2008, 33(2):278-291.
58. Gomberg-Maitland M., Maitland M., Barst R., et al. Adosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension. Clin Pharmacol Ther 2010, 87(3):303-310.
59. Humbert M., Simonneau G., Dinh-Xuan A. Whistleblowers. Eur Respir J 2011, 38(3):510-511.
60. Montani D., Bergot E., Gunther S., et al. Pulmonary arterial hypertension in patients treated by Dasatinib. Circulation 2012, 125(17):2128-2137.
61. Herve P., Launay J., Scrobohaci M., et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med 1995, 99(3):249-254.
62. Launay J., Herve P., Peoc'h K., et al. Function of theserotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat Med 2002, 8(10):1129-1135.
63. Dempsie Y., MacLean M. Pulmonary hypertension: therapeutic targets within the serotonin system. BrJ Pharmacol 2008, 155(4):455-462.
64. Roth B.L. Drugs and valvular heart disease. NEngl J Med 2007, 356(1):6-9.
65. Eddahibi S., Humbert M., Fadel E., et al. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. JClin Invest 2001, 108(8):1141-1150.
66. Eddahibi S., Chaouat A., Morrell N., et al. Polymorphism of the serotonin transporter gene and pulmonary hypertension in chronic obstructive pulmonary disease. Circulation 2003, 108(15):1839-1844.
67. Zhai F., Zhang X., Wang H. Fluoxetine protects against monocrotaline-induced pulmonary arterial hypertension: potential roles of induction of apoptosis and upregulation of Kv1.5 channels in rats. Clin Exp Pharmacol Physiol 2009, 36(8):850-856.
68. Shah S., Gomberg-Maitland M., Thenappan T. Selective serotonin reuptake inhibitors and the incidence and outcome of pulmonary hypertension. Chest 2009, 136(3):694-700.
69. Dumitrascu R., Kulcke C., Konigshoff M., et al. Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats. Eur Respir J 2011, 37(5):1104-1118.
70. Ghofrani H., Al-Hitit H., Vonk-Noordegraaf H., et al. Proof-of-concept study to investigate the efficacy, haemodynamics and tolerability of teguride vs placebo in subjects with pulmonary arterial hypertension: results of a double-blind randomised, prospective IIa study. Am J Respir Crit Care Med 2012, 185:A2496.
71. Hamidi S., Prabhakar S., Said S. Enhancement of pulmonary vascular remodelling and inflammatory genes with VIP gene deletion. Eur Respir J 2008, 31(1):135-139.
72. Said S., Hamidi S., Dickman K., et al. Moderate pulmonary arterial hypertension in male mice lacking the vasoactive intestinal peptide gene. Circulation 2007, 115(10):1260-1268.
73. Hamidi S., Lin R., Szema A., et al. VIP and endothelin receptor antagonist: an effective combination against experimental pulmonary arterial hypertension. Respir Res 2011, 12:141.
74. Petkov V., Mosgoeller W., Ziesche R., et al. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. JClin Invest 2003, 111(9):1339-1346.
75. Galie N, Badesch D, Fleming T, et al. Effects of inhaled aviptadil (vasoactive intestinal peptide) in patients with pulmonary arterial hypertension (PAH): results from a phase II study. http://dx.doi.org/10.1164/ajrccm-conference.2010.181.1_MeetingAbstracts.A2516.
76. Kao P.N. Simvastatin treatment of pulmonary hypertension: an observational case series. Chest 2005, 127(4):1446-1452.
77. Laufs U., Marra D., Node K. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1). JBiol Chem 1999, 274(31):21926-21931.
78. Zhao L., Sebkhi A., Ali O., et al. Simvastatin and sildenafil combine to attenuate pulmonary hypertension. Eur Respir J 2009, 34(4):948-957.
79. Wilkins M.R., Ali O., Bradlow W., et al. Simvastatin as a treatment for pulmonary hypertension trial (SiPHT). Am J Respir Crit Care Med 2010, 181(10):1106-1113.
80. Kawut S.M., Bagiella E., Lederer D.J., et al. Randomized clinical trial of aspirin and simvastatin for pulmonary arterial hypertension: ASA-STAT. Circulation 2011, 123(25):2985-2993.
81. Zeng W., Xiong C., Zhao L., et al. Atorvastatin in pulmonary arterial hypertension (APATH) study. Eur Respir J 2012, 40(1):67-74.
82. Saadjian A., Philip-Joet F., Paganelli F. Long-term effects of cicletanine on secondary pulmonary hypertension. JCardiovasc Pharmacol 1998, 31(3):364-371.
83. US NIH ClinicalTrials.gov. Study of cicletanine for pulmonary arterial hypertension (PAH). Available at: Last updated August 22, 2012. Last Accessed September 29, 2013. http://www.clinicaltrials.gov/show/NCT/00832507.
84. Guilluy C., Eddahibi S., Agard C., et al. RhoA and Rho kinase activation in human pulmonary hypertension: role of 5-HT signaling. Am J Respir Crit Care Med 2009, 179(12):1151-1158.
85. Oka M., Fagan K., Jones P. Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension. Br J Pharmacol 2008, 155(4):444-454.
86. Abe K., Shimokawa H., Morikawa K., et al. Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ Res 2004, 94(3):385-393.
87. Fukumoto Y., Matoba T., Ito A., et al. Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart 2005, 91(3):391-392.
88. Hardavella G., Dionellis G., Kantza C. Latest therapeutic novelties and patents in pulmonary hypertension. Recent Pat Cardiovasc Drug Discov 2011, 6(1):55-60.
89. Dahal B., Kosanovic D., Pamarthi P., et al. Therapeutic efficacy of azaindole-1 in experimental pulmonary hypertension. Eur Respir J 2010, 36(4):808-818.
90. McMurtry M., Bonnet S., Wu X., et al. Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis. Circ Res 2004, 95(8):830-840.
91. Dewachter L., Dewachter C., Naeije R. New therapies for pulmonary arterial hypertension: an update on current bench to bedside translation. Expert Opin Investig Drugs 2010, 19(4):469-488.
92. US NIH ClinicalTrials.gov. Dichloroacetate (DCA) for the treatment of pulmonary arterial hypertension. Available at: 2010. Last updated November 3, 2011. Last Accessed September 29, 2013. http://clinicaltrials.gov/ct2/show/NCT01083524?term=Dichloroacetate%26rank=1.
93. Shenoy V., Qi Y., Katovich M., et al. ACE2, a promising therapeutic target for pulmonary hypertension. Curr Opin Pharmacol 2011, 11(2):150-155.
94. Takahashi Y., Haga S., Ishizaka Y., et al. Autoantibodies to angiotensin-converting enzyme 2 in patients with connective tissue diseases. Arthritis Res Ther 2010, 12(3):R85.
95. Dai H., Guo Y., Guang X., et al. The changes of serum angiotensin-converting enzyme 2 in patients with pulmonary arterial hypertension due to congenital heart disease. Cardiology 2013, 124(4):208-212.
96. Yamazato Y., Ferreira A., Hong K., et al. Prevention of pulmonary hypertension by angiotensin-converting enzyme 2 gene transfer. Hypertension 2009, 54(2):365-371.
97. Johnson J., Perrien A., Schuster M., et al. Cytoskeletal defects in BMPR2-associated pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 2012, 302(5):L474-L484.
98. Ferreira A., Shenoy V., Yamazato Y., et al. Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension. Am J Respir Crit Care Med 2009, 179(11):1048-1054.
99. Hennigan S., Channick R., Silverman G. Rituximab treatment of pulmonary arterial hypertension associated with systemic lupus erythematosus: a case report. Lupus 2008, 17(8):754-756.
100. US NIH ClinicalTrials.gov. Rituximab for treatment of systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH). Available at: 2013. Last updated August 17, 2013. Last Accessed September 29, 2013. http://clinicaltrials.gov/ct2/show/NCT01086540.
101. Sobolewski A., Rudarakanchana N., Upton P., et al. Failure of bone morphogenetic protein receptor trafficking in pulmonary arterial hypertension: potential for rescue. Hum Mol Genet 2008, 17(20):3180-3190.
102. Drake K., Dunmore B., McNelly L., et al. Correction of nonsense BMPR2 and SMAD9 mutations by ataluren in pulmonary arterial hypertension. Am J Respir Cell Mol Biol 2013, 49(3):403-409.
103. Meloche J., Courchesne A., Barrier M., et al. Critical role for the advanced glycation end-products receptor in pulmonary arterial hypertension etiology. JAm Heart Assoc 2013, 2(1):e005157.
104. Houssaini A., Abid S., Mouraret N., et al. Rapamycin reverses pulmonary-artery smooth-muscle-cell proliferation in pulmonary hypertension. Am J Respir Cell Mol Biol 2013, 48(5):568-577.
105. Zhao L., Chen C., Hajji N., et al. Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid. Circulation 2012, 126(4):455-467.
106. Bogaard H., Mizuno S., Hussaini A., et al. Suppression of histone deacetylases worsens right ventricular dysfunction after pulmonary artery banding in rats. Am J Respir Crit Care Med 2011, 183(10):1402-1410.
107. Robbins I., Hemnes A., Gibbs J., et al. Safety of sapropterin dihydrochloride (6r-bh4) in patients with pulmonary hypertension. Exp Lung Res 2011, 37(1):26-34.
108. Schatteman G., Dunnwald M., Jiao C. Biology of bone marrow-derived endothelial cell precursors. Am J Physiol Heart Circ Physiol 2007, 292(1):H1-H18.
109. Launay J., Herve P., Callebert J., et al. Serotonin 5-HT2B receptors are required for bone-marrow contribution to pulmonary arterial hypertension. Blood 2011, 119(7):1772-1780.
110. Gambaryan N., Perros F., Montani D., et al. Targeting of c-kit+ haematopoietic progenitor cells prevents hypoxic pulmonary hypertension. Eur Respir J 2011, 37(6):1392-1399.
111. Zhao Y., Courtman D., Deng Y., et al. Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease. Circ Res 2005, 96(4):442-450.
112. Wang X., Zhang F., Shang Y., et al. Transplantation of autologous endothelial progenitor cells may be beneficial in patients with idiopathic pulmonary arterial hypertension: a pilot randomized controlled trial. JAm Coll Cardiol 2007, 49(14):1566-1571.
113. US NIH ClinicalTrials.gov. Pulmonary hypertension: assessment of cell therapy (PHACeT). Available at: Last updated March 7, 2013. Last Accessed September 29, 2013. http://clinicaltrials.gov/ct2/show/NCT00469027?term=PHACeT%26rank=12010.